Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Amgen Neupogen

Executive Summary

Amgen Neupogen: Granulocyte colony stimulating factor use in acute myeloid leukemia patients undergoing induction and consolidation chemotherapy unanimously recommended by FDA's Biological Response Modifiers Advisory Committee July 25. A 521-patient Phase III trial showed neutropenic episodes after induction therapy to be five days shorter compared to placebo and seven days less after consolidation treatment...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel